Paola Circosta

List of Publications by Year
in descending order

33 papers	1,592 citations	430874 18 h-index	477307 29 g-index
35 all docs	35 docs citations	35 times ranked	2811 citing authors

#	Article	IF	Citations
1	Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. Cell Death and Disease, 2022, 13, .	6.3	1
2	The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia. Cancers, 2021, 13, 1003.	3.7	21
3	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. Cancers, 2021, 13, 1311.	3.7	21
4	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Biphenyl Moiety. Journal of Medicinal Chemistry, 2021, 64, 5404-5428.	6.4	19
5	Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells. Journal of Clinical Medicine, 2021, 10, 5805.	2.4	7
6	Inhibition of bromodomain and extraâ€terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia. Journal of Cellular and Molecular Medicine, 2020, 24, 1650-1657.	3.6	18
7	Nanocarriers as Magic Bullets in the Treatment of Leukemia. Nanomaterials, 2020, 10, 276.	4.1	38
8	Chronic myeloid leukemia stem cells. Leukemia, 2019, 33, 1543-1556.	7.2	127
9	An Ig Transmembrane Domain Motif Improves the Function of TCRs Transduced in Human T Cells: Implications for Immunotherapy. Journal of Immunotherapy, 2019, 42, 97-109.	2.4	2
10	Bone marrow microenvironment: The guardian of leukemia stem cells. World Journal of Stem Cells, 2019, 11, 476-490.	2.8	29
11	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. OncoImmunology, 2018, 7, e1341032.	4.6	11
12	Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 6034-6055.	6.4	57
13	Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. Immunotherapy, 2018, 10, 753-767.	2.0	0
14	Immature CML cells implement a BMP autocrine loop to escape TKI treatment. Translational Cancer Research, 2018, 7, S722-S725.	1.0	3
15	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood, 2016, 127, 221-232.	1.4	97
16	Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition. Human Gene Therapy, 2015, 26, 220-231.	2.7	15
17	miR-223 Is a Coordinator of Breast Cancer Progression as Revealed by Bioinformatics Predictions. PLoS ONE, 2014, 9, e84859.	2.5	61
18	The molecular and functional characterization of clonally expanded CD8+ TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA). Clinical Immunology, 2014, 152, 152-163.	3.2	20

#	Article	IF	Citations
19	High Basal Î³H2AX Levels Sustain Self-Renewal of Mouse Embryonic and Induced Pluripotent Stem Cells. Stem Cells, 2012, 30, 1414-1423.	3.2	75
20	Molecular and Functional Analysis of Peripheral Lymphocytes in Churg Strauss Syndrome Reveals Several Monoclonal Expansions of CD8+ Cells with a Th1/Proinflammatory Profile. Blood, 2012, 120, 1051-1051.	1.4	0
21	Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. Journal of Biotechnology, 2011, 156, 218-226.	3.8	14
22	TCR transfer induces TCR-mediated tonic inhibition of RAG genes in human T cells. Molecular Immunology, 2011, 48, 1369-1376.	2.2	2
23	Retargeting of Citokine-Induced Killer (CIK) Cells with Molecularly Engrafted T-Cell Receptors (TCR): A Preclinical in Vitro and In Vivo Study. Blood, 2011, 118, 1917-1917.	1.4	0
24	A CD8+ T-Cell Clone Directed Against AML Blasts that Recognizes a Tumor Specific Antigen Expressed Also by Solid Tumors. Blood, 2010, 116, 4289-4289.	1.4	0
25	T Cell Receptor (TCR) Gene Transfer with Lentiviral Vectors Allows Efficient Redirection of Tumor Specificity in Naive and Memory T Cells Without Prior Stimulation of Endogenous TCR. Human Gene Therapy, 2009, 20, 1576-1588.	2.7	34
26	Clonal CD8+ TCR-VÎ² expanded populations with effector memory phenotype in Churg Strauss Syndrome. Clinical Immunology, 2008, 128, 94-102.	3.2	18
27	Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5090-5095.	7.1	147
28	Lentiviral Transduction of Primary Myeloma Cells with CD80 and CD154 Generates Antimyeloma Effector T Cells. Human Gene Therapy, 2005, 16, 445-456.	2.7	5
29	Leukemia-Derived Immature Dendritic Cells Differentiate into Functionally Competent Mature Dendritic Cells That Efficiently Stimulate T Cell Responses. Journal of Immunology, 2004, 173, 2855-2865.	0.8	48
30	The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Experimental Hematology, 2003, 31, 495-503.	0.4	31
31	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood, 2003, 101, 1962-1969.	1.4	139
32	Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood, 2001, 97, 2777-2783.	1.4	299
33	MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leukemia Research, 1999, 23, 127-136.	0.8	233